LaSalle’s Price REFLECTS Q2 Miss and 4 Stock Analyses Beginning the Week
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX): After the FDA approved Kyprolis, Maxim raised their price target for Onyx Pharmaceuticals. They reiterate a Buy rating on their stock.
Schlumberger Limited (NYSE:SLB): Schlumberger reported stronger than expected results for the second quarter, however, RBC Capital believes that, even though, the outlook for the North Sea and Russia are both positive, the U.S. frac margins are likely to decline in 2012. The firm maintains an Outperform rating on their stock.
NuVasive, Inc. (NASDAQ:NUVA): Although RBC Capital expects NuVasive, Inc. to deliver, beat and raise their second quarter results, the firm believes that this outcome is already largely priced into the stock. They view the stock’s risk/reward ratio results as unfavorable. However, there is still confidence in the company’s outlook. NuVasive maintains an Outperform rating.
Gaylord Entertainment Co. (NYSE:GET): FBR Capital anticipates that a vote against Gaylord Entertainment’s plan, to convert to a Real Estate Investment Trust, from their largest stakeholder, TRT Holdings, will not be enough to block the transaction. However, they believe the stock’s valuation indicates that the deal will occur. FBR thinks the downside risk outweighs the potential upside. They keep a Market Perform rating and a $31 price target on their shares.
LaSalle Hotel Properties (NYSE:LHO): RBC Capital believes that LaSalle’s current stock price reflects their increased renovation plans for 2013, as well as recurring elements of their second quarter miss. The firm maintains a $32 target and Outperform rating on their stock.
Don’t Miss: The Dow is NOT Lovin’ McDonald’s Right Now.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.